Evogene Management

How has Ofer Haviv's remuneration changed compared to Evogene's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$401k	US$390k	-US$24m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	US$464k	US$415k	-US$27m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$530k	US$420k	-US$28m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$592k	US$367k	-US$23m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$538k	US$366k	-US$18m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$517k	US$324k	-US$21m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$21m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$649k	US$359k	-US$21m

Compensation vs Market: Ofer's total compensation ($USD401.00K) is below average for companies of similar size in the US market ($USD648.89K).

Compensation vs Earnings: Ofer's compensation has been consistent with company performance over the past year.

CEO

Ofer Haviv (58 yo)

19.9yrs

Tenure

US$401,000

Compensation

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ofer Haviv	CEO & President	19.9yrs	US$401.00k	no data
Brian Ember	Chief Executive Officer of AgPlenus Ltd	2.9yrs	US$456.00k	no data
Elran Haber	Chief Executive Officer of Biomica Ltd	6.8yrs	US$339.00k	0% $ 0
Amit Noam	Chief Executive Officer of Lavie Bio Ltd.	1.6yrs	US$606.00k	no data
Yaron Eldad	Chief Financial Officer	2.6yrs	no data	0% $ 0
Rachel Gerber	Head of Investor Relations	1.4yrs	no data	no data
Sassi Masliah	Vice President of Corporate Development	2.8yrs	US$304.00k	0% $ 0
Liat Wejgman	Vice President of Human Resources	2.8yrs	no data	no data
Eyal Ronen	Executive Vice President of Business Development	2.4yrs	no data	0% $ 0
Yoash Zohar	Chief Executive Officer of Casterra Ag Ltd.	less than a year	no data	no data
Dan Gelvan	Chief Executive Officer of Ag Plenus Ltd.	less than a year	no data	no data
Russ Putland	Vice President of Commercial of Lavie Bio Ltd.	no data	no data	no data

2.6yrs

Average Tenure

53yo

Average Age

Experienced Management: EVGN's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dan Falk	Independent Director	3yrs	no data	0% $ 0
Nir Nimrodi	Independent Director	2yrs	no data	0% $ 0
Leon Recanati	Independent Director	19.5yrs	no data	1.56% $ 162.9k
Sarit Weiss-Firon	Independent Chairperson of the Board	8.3yrs	no data	0% $ 0
Oded Shoseyov	Independent Director	6yrs	no data	0% $ 0
Adrian Percy	Independent Director	5.8yrs	no data	0% $ 0
Eran Segal	Scientific Advisor	2.8yrs	no data	no data

5.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: EVGN's board of directors are considered experienced (5.8 years average tenure).

Evogene Management

Management criteria checks 4/4

Key information

Recent management updates

Evogene Ltd. Announces Executive Changes

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$6.00

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Evogene unit launches 2nd-gen medical cannabis products in Israel

Lavie Bio appoints Guri Oron as CEO

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene regains compliance with Nasdaq's minimum bid price requirement

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

Price target decreased to US$10.33

High number of new directors

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Price target decreased to US$10.33

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Evogene EPS beats by $0.01, beats on revenue

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

Price target raised to US$15.00

New 90-day high: US$7.68

New 90-day high: US$5.95

New 90-day high: US$5.63

Evogene unit - Canonic inks cultivation deal for medical cannabis varieties

AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program

New 90-day high: US$4.31

Evogene: Q3 Update And Upcoming Catalysts

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

New 90-day high: US$4.16

New 90-day high: US$3.09